| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Vivos Therapeutics, Inc. | Chief Financial Officer | Stock Option (Right to Buy) | 180,533 | $476,607 | $2.64 | 26 Nov 2024 | Direct |
| Vivos Therapeutics, Inc. | Chief Financial Officer | Common Stock | 80 | $42 | $0.5300 | 26 Nov 2024 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| VVOS | Vivos Therapeutics, Inc. | 26 Nov 2024 | 1 | +$394,767 | 4 | Chief Financial Officer | 27 Nov 2024, 16:43 |
| VVOS | Vivos Therapeutics, Inc. | 20 Jun 2024 | 1 | +$35,700 | 4 | Chief Financial Officer | 28 Jun 2024, 20:53 |
| VVOS | Vivos Therapeutics, Inc. | 23 Dec 2022 | 1 | +$96,000 | 4 | Chief Financial Officer | 28 Dec 2022, 20:45 |
| VVOS | Vivos Therapeutics, Inc. | 25 Feb 2022 | 1 | +$163,500 | 4 | Chief Financial Officer | 28 Feb 2022, 17:50 |
| VVOS | Vivos Therapeutics, Inc. | 31 Aug 2021 | 4 | +$1,763,008 | 4 | Chief Financial Officer | 02 Sep 2021, 21:27 |
| VVOS | Vivos Therapeutics, Inc. | 25 May 2021 | 1 | +$5,290 | 4 | Chief Financial Officer | 25 May 2021, 21:45 |